Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Open accessThe DOI matches its Crossref record; 132 of the 133 references it cites were found in a registry or an index; 40 of the 58 sources its claims cite were checked for support.
Abstract
The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line therapeutics for Candida infections. Here, we provide the first global analysis of mutations accompanying the evolution of fungal drug resistance in a human host utilizing a series of C. glabrata isolates that evolved echinocandin resistance in a patient treated with the echinocandin caspofungin for recurring bloodstream candidemia. Whole genome sequencing identified a mutation in the drug target, FKS2, accompanying a major resistance increase, and 8 additional non-synonymous mutations. The FKS2-T1987C mutation was sufficient for echinocandin resistance, and associated with a fitness cost that was mitigated with further evolution, observed in vitro and in a murine model of systemic candidemia. A CDC6-A511G(K171E) mutation acquired before FKS2-T1987C(S663P), conferred a small resistance increase. Elevated dosage of CDC55, which acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated fitness. To discover strategies to abrogate echinocandin resistance, we focused on the molecular chaperone Hsp90 and downstream effector calcineurin. Genetic or pharmacological compromise of Hsp90 or calcineurin function reduced basal tolerance and resistance. Hsp90 and calcineurin were required for caspofungin-dependent FKS2 induction, providing a mechanism governing echinocandin resistance. A mitochondrial respiration-defective petite mutant in the series revealed that the petite phenotype does not confer echinocandin resistance, but renders strains refractory to synergy between echinocandins and Hsp90 or calcineurin inhibitors. The kidneys of mice infected with the petite mutant were sterile, while those infected with the HSP90-repressible strain had reduced fungal burden. We provide the first global view of mutations accompanying the evolution of fungal drug resistance in a human host, implicate the premier compensatory mutation mitigating the cost of echinocandin resistance, and suggest a new mechanism of echinocandin resistance with broad therapeutic potential.
Overview
CoChat Summary
## TL;DR
This study tracks echinocandin resistance as it evolved over 10 months in a patient with recurrent *Candida glabrata* candidemia, using whole-genome sequencing plus functional genetics. The main resistance mutation was *FKS2* T1987C (S663P), which was sufficient for resistance but carried a fitness cost that was later mitigated; the paper also shows that Hsp90 and calcineurin are required for resistance and for caspofungin-induced *FKS2* expression.
## Key findings
- Whole-genome sequencing of early isolate A and late isolate G found 26 single-nucleotide variants total, with 17 in open reading frames and 9 non-synonymous mutations; these were mapped across the 7-isolate series.
- The *FKS2* T1987C (S663P) mutation was sufficient to confer echinocandin resistance in a susceptible laboratory strain, but it reduced fitness in RPMI at 37°C; the paper reports this fitness cost was mitigated with further evolution.
- A *CDC6* A511G (K171E) mutation conferred a small increase in echinocandin resistance, and increased dosage of *CDC55* ameliorated the fitness cost associated with the *FKS2* mutation.
- Pharmacological or genetic compromise of Hsp90 or calcineurin reduced basal tolerance/resistance, and caspofungin-induced *FKS2* expression was blocked by deletion of *CNB1* and reduced when *HSP90* was repressed.
- A petite mutant in the series was not intrinsically echinocandin-resistant, but was refractory to the synergy between caspofungin and Hsp90/calcineurin inhibitors; in mice, kidneys infected with the petite mutant were sterile, and reduced *HSP90* lowered kidney fungal burden.
## Methods
- Clinical case series: 7 related *C. glabrata* bloodstream isolates collected over a 10-month period from one patient with recurrent candidemia during caspofungin treatment.
- Genomics and validation: whole-genome sequencing of isolates A and G on Illumina Genome Analyzer II (5.1 and 3.8 million 76-bp reads; 22–30× coverage), alignment to CBS138, variant calling, Sanger validation, and Sanger mapping of candidate mutations across isolates B–F.
- Functional assays: broth microdilution MIC testing, qRT-PCR for *FKS2*, *CNB1*, and *HSP90* expression, growth-curve analysis, engineered mutant/complement strains, and a murine disseminated infection model in CD1 mice (n = 10 per group).
## Limitations
- The paper states that whether the original petite mutant arose in the human host or during sampling “remains unknown.”
- The authors note that methionine levels in mice may not have been sufficient to fully repress the MET3 promoter, which may explain why *HSP90* depletion caused only a modest reduction in fungal burden in vivo.
- Evident from the text: the study centers on a single patient case series, so the clinical evolutionary trajectory is detailed but not shown to be broadly representative.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
26 Valid · 2 Not valid · 8 Not checked · 151 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Thus far, the only echinocandin resistance mechanism described is mutation in the drug target, Fks, particularly in highly conserved hot spots regions [33], [36]–[39].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Introduction The emergence of drug resistance is an evolutionary process with a profound impact on human health. The widespread deployment of antimicrobial agents in medicine and agriculture exerts strong selection for organisms with enhanced capacity to survive and reproduce in the presence of drug, which has led to the rapid emergence of drug resistance in diverse pathogen populations [1]–[4]. The evolution of drug resistance compromises the efficacy of drugs that we depend on critically for a myriad of therapeutic interventions, and has striking economic consequences. The annual cost attributable to the evolution of drug resistance in the United States alone exceeds $33 billion to cover treatment of patients with drug-resistant infections, additional pesticides required to manage resistant pests, and loss of crops to resistant pests [5]. The emergence of drug resistance in fungal pathogens is of particular concern given the increasing incidence of invasive fungal infections, and the limited number of antifungal drugs. Fungi can cause life-threatening infectious disease in immunocompromised hosts, as well as in healthy humans, and the incidence of fungal bloodstream infections has increased by 207% in recent decades [6]–[8]. Fungi are eukaryotes and share close evolutionary relationships with their human hosts, which limits the number of drug targets that can be exploited to selectively kill fungal pathogens yet minimize host toxicity [1], [3]. Even with current treatment options, mortality rates due to invasive fungal infections can reach 50–90% depending on the pathogen and patient population [7], [8], demanding new strategies to prevent the evolution of drug resistance and enhance the efficacy of antifungal drugs. The evolution of drug resistance is contingent on genetic variability, the ultimate source of which is mutation. One of the most fundamental questions of central importance to predicting and preventing the evolution of drug resistance is which mutations accompany the evolution of drug resistance in the human host. Developments in sequencing technology [9]–[11] now enable this question to be addressed on a genome-wide scale to reveal the identity of mutations that either confer drug resistance in a clinically relevant context or that modify the fitness consequences of resistance mutations. Whole genome sequencing has been applied to bacteria and has revealed principles underpinning the evolution and transmission of drug-resistant pathogens [12], risk factors for the evolution of drug resistance [13], and population dynamics during the evolution of drug resistance in vitro [14]. In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15], [16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechanisms of resistance that evolve in the human host [1], [17]. However, a global approach to mapping mutations that underpin the evolution of fungal drug resistance has yet to be achieved. Candida glabrata is a leading fungal pathogens of humans and provides a particularly powerful system for studying the evolution of drug resistance in a human host. Candida species are the fourth most common cause of hospital acquired blood-stream infections and are the most prevalent cause of invasive fungal infection worldwide, with mortality rates approaching 50% [7], [18]. C. glabrata is now second to C. albicans as the most prevalent Candida species isolated from clinical specimens [7], [8], [19]. This is due in part to both intrinsic and rapidly acquired resistance of C. glabrata to the azoles, which are the most widely used class of antifungal drugs and inhibit the biosynthesis of the key sterol in fungal cell membranes, ergosterol [20]. As a consequence, the echinocandins are the front-line therapeutic agent for C. glabrata infections [19]. C. glabrata is closely related to the model yeast Saccharomyces cerevisiae and is placed within the Saccharomyces clade rather than the Candida clade to which the leading cause of candidiasis, C. albicans, belongs [21]–[23]. It is thought that C. glabrata emerged as a human pathogen independently from other Candida species. Notably, gene families associated with pathogenicity in C. albicans including iron acquisition and host cell adhesion and invasion are absent from C. glabrata [24]. C. glabrata is an obligate haploid and mating has never been reported, although two mating types, mating type switching, and other mating and meiotic machinery have been described [25]–[27]. To increase genetic diversity C. glabrata undergoes chromosomal translocations and variation in gene copy number [28], [29], mechanisms that also contribute to C. albicans resistance to azoles [16], [30], [31]. As a haploid, analysis of C. glabrata genome sequence is more facile than in diploids such as C. albicans, where mitotic recombination and gene conversion can inflate the number of polymorphisms that accrue and obscure the signal of those functionally associated with drug resistance or adaptation to the host. Compared to the most widely used antifungal drugs in clinical use for the treatment of systemic infections, the azoles, mechanisms of resistance remain more limited for echinocandins. The echinocandins are the only novel class of antifungal drugs approved for clinical use in decades and target the biosynthesis of the key fungal cell wall component, 1,3-β-D-glucan [3], [20], [32]. The 1,3-β-D-glucan synthases are encoded by FKS1, FKS2, and FKS3 in S. cerevisiae, C. glabrata, and C. albicans, and require a regulatory subunit encoded by RHO1 for activity [3], [20], [32], [33]. It is thought that the echinocandins bind to and inhibit the Fks protein; however, the exact mechanism of inhibition remains unknown [33]. Although the echinocandins have been in clinical use since only 2001, there have been numerous reports of C. glabrata echinocandin resistance in patients [34]–[37]. Thus far, the only echinocandin resistance mechanism described is mutation in the drug target, Fks, particularly in highly conserved hot spots regions [33], [36]–[39]. Such mutations can reduce echinocandin susceptibility of 1,3-β-D-glucan synthase by 2 to 3 log orders relative to the wild-type enzyme [36]. Additional resistance mechanisms may remain to be described given that Fks mutations have not been identified in some echinocandin-resistant isolates [20], [37], [40], and that isolates with identical Fks mutations exhibit different resistance phenotypes with distinct responses to cellular perturbations [41]. Even with azoles, for which resistance mechanisms have been studied for decades, new resistance mechanisms and modulators of resistance continue to be discovered, expanding the repertoire of strategies employed by fungi to survive drug exposure to include mutation in the drug target, overexpression of multidrug-efflux transporters, and metabolic alterations that minimize drug toxicity [3], [20], [32]. In addition to these canonical resistance mechanisms where mutations in relevant genes confer resistance, there is also an emergent paradigm in which regulators of cellular stress responses are crucial for enabling the evolution and maintenance of drug resistance [3], [20], [32]; while mutations in these regulators have not been identified as a cause of resistance, stress response regulators are key resistance modulators critical for enabling the phenotypic effects of resistance acquired by diverse mechanisms. Beyond mapping mutations that confer resistance, there is pressing clinical need to elucidate strategies to block the evolution of drug resistance and abrogate resistance once it has evolved. One of the most well studied examples of a protein that governs the emergence and maintenance of fungal drug resistance is the molecular chaperone Hsp90. Hsp90 regulates the folding and function of diverse client proteins, including many signal transducers [42], [43]. In C. albicans, compromise of Hsp90 function reduces basal tolerance and resistance of clinical isolates to both the azoles and the echinocandins [41], [44], [45]. Hsp90 enables crucial responses to drug-induced stress by orchestrating signaling through the protein phosphatase calcineurin and the protein kinase C (PKC) cell wall integrity signaling cascade [41], [46]. Hsp90 stabilizes the catalytic subunit of calcineurin and the terminal mitogen-activated protein kinase (MAPK) in the Pkc1 cell wall integrity pathway. Genetic or pharmacological compromise of Hsp90 function can enhance the efficacy of antifungals against C. albicans in multiple metazoan models of infection [41], [45]. Notably, Hsp90's role in governing cellular responses to azoles in C. albicans is conserved in S. cerevisiae [44], [47]. In contrast, Hsp90 and calcineurin play a key role in crucial cellular responses to echinocandins in C. albicans, but not in S. cerevisiae [41]. Whether Hsp90 influences drug resistance in C. glabrata remains entirely unknown. In C. glabrata, both calcineurin and PKC signaling have been implicated in basal tolerance to echinocandins [48], [49], though the role of Hsp90 remains unknown as does the impact of any of these regulators on bona fide echinocandin resistance. Here, we provide the first global analysis of mutations accompanying the evolution of fungal drug resistance in a human host. We report on a series of C. glabrata isolates that evolved echinocandin resistance in a patient undergoing treatment with the echinocandin caspofungin for recurring C. glabrata candidemia over a 10-month period. Whole genome sequencing revealed that a mutation occurred in the gene encoding the drug target, FKS2, accompanying a major increase in resistance, as well as 8 other non-synonymous mutations in genes not previously implicated in echinocandin resistance, including CDC6 and CDC55. The FKS2-T1987C(S663P) mutation was sufficient to confer echinocandin resistance in a susceptible laboratory strain; however, the mutant allele also imparted a growth defect in clinically relevant conditions using RPMI medium at 37°C. The fitness cost of resistance was mitigated with further evolution, and this trend was also observed in a murine model of disseminated infection. A CDC6-A511G (K171E) mutation acquired prior to the FKS2-T1987C(S663P) mutation was sufficient to confer a small increase in resistance. Elevated dosage of CDC55, which acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated the fitness cost imparted by the FKS2 mutation. To uncover mechanisms that abrogate echinocandin resistance, we turned to Hsp90 and found that genetic or pharmacological compromise of C. glabrata Hsp90 function reduced basal tolerance and resistance of clinical isolates. Compromising calcineurin function pharmacologically or genetically phenocopied compromising Hsp90 function. Caspofungin induced FKS2 expression in a manner that depended upon Hsp90 and calcineurin, providing a molecular mechanism by which Hsp90 and calcineurin regulate echinocandin resistance. Furthermore, one of the clinical isolates in the series is a petite mutant based on morphology and inability to respire; although the petite phenotype was not intrinsically involved in echinocandin resistance, it imparted resistance to the combination of echinocandins and inhibitors of Hsp90 or calcineurin. In a mouse model of candidemia, the petite mutant was rapidly cleared and completely avirulent while infection with the HSP90-repressible strain yielded a reduced fungal burden compared to wild type. Thus, our results provide the first global view of mutations that accompany the evolution of fungal drug resistance in a human host, implicate the first compensatory mutation that mitigates the cost of echinocandin resistance, and suggest a new molecular mechanism regulating echinocandin resistance, with broad therapeutic potential.
What the sources say
- Disputedcites [33] DS Perlin, 2007, Resistance to echinocandin-class antifungal drugs., Drug Resist Updat sourceExperimental — accuracy not yet measured
Section 12 says Fks1 mutations are the only mechanism firmly associated with clinical echinocandin resistance, and sections 7–8 locate those mutations in conserved hot spots. But section 11 describes echinocandin-resistant fungi whose resistance indicates an alternative mechanism independent of Fks1. The claim's unqualified assertion that Fks mutation is the only described resistance mechanism is therefore contrary to the source. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not matchedcites [36]–[39]
A range of references, not one source.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Results > The FKS2 T1987C (S663P) mutation confers echinocandin resistance and imparts a fitness deficit in a C. glabrata laboratory strain To determine which of the mutations identified by whole genome sequencing contributes to echinocandin resistance we first turned to the most likely candidate resistance gene, FKS2. The FKS2 mutation that emerged in isolate D and was maintained throughout the rest of the series (T1987C) results in substitution of a serine to proline at amino acid 663 in the target of the echinocandins. This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37]. In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36]. While there is an association of FKS mutations with resistance, and biochemical data support the resistance mechanism, it has only been conclusively demonstrated that such mutations are sufficient to confer echinocandin resistance in S. cerevisiae [82], [83]. To test whether Fks2 S663P is sufficient to confer echinocandin resistance, we introduced the T1987C mutation into the sensitive laboratory strain BG2 using a strategy involving single-stranded DNA containing the mutation and a silent marker, followed by selection of transformants on medium containing caspofungin. No echinocandin-resistant colonies were obtained following control transformations with single-stranded DNA containing the equivalent wild-type sequence or with a water control, while many resistant colonies were obtained with the sequence containing the T1987C mutation. We assessed resistance of four sequence-verified transformants that harboured both the T1987C and silent mutation via minimum inhibitory concentration (MIC) assays. The transformants displayed resistance similar to clinical isolate G (Figure 2A). Thus, Fks2 S663P is sufficient to confer echinocandin resistance in a susceptible laboratory strain of C. glabrata. Given that specific Fks amino acid substitutions that decrease sensitivity of the 1,3-β-D-glucan synthase enzyme to echinocandins also reduce the enzyme catalytic capacity, the Fks2 S663P mutation may confer a fitness cost in terms of reduced growth or viability in the absence of the drug [36], [39]. To determine if the FKS2 mutations compromises fitness, we monitored growth kinetics of the lab strain BG2 and the progeny harbouring the Fks2 S663P substitution. In clinically relevant conditions, RPMI at 37°C, we found that strains harbouring the Fks2 S663P substitution displayed significantly reduced fitness relative to the parental wild-type laboratory strain BG2 (P<0.01, area under the curve followed by ANOVA, Bonferroni's Multiple Comparison Test, Figure 2B, left panel). Furthermore, we observed a significant reduction in fitness between isolate A and isolate D (P<0.001), which is rescued to some extent in isolate G (P<0.01, Figure 2B, right panel). Thus, the FKS2 mutation that emerged in clinical isolate D is sufficient to confer a high level of caspofungin resistance equivalent to that observed in the late isolate G, however, it is also associated with a cost in terms of reduced fitness in the absence of the drug.
What the sources say
- Supportedcites [36] G Garcia-Effron, 2009, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint., Antimicrob Agents Chemother source
The Results state that mutant enzymes’ Km values were not statistically different from wild-type values and explicitly say the substitutions do not change the enzyme’s binding affinity for echinocandin drugs. The passage discusses Fks2p mutants among the enzymes studied. (LLM, conf=0.93)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Results > The FKS2 T1987C (S663P) mutation confers echinocandin resistance and imparts a fitness deficit in a C. glabrata laboratory strain To determine which of the mutations identified by whole genome sequencing contributes to echinocandin resistance we first turned to the most likely candidate resistance gene, FKS2. The FKS2 mutation that emerged in isolate D and was maintained throughout the rest of the series (T1987C) results in substitution of a serine to proline at amino acid 663 in the target of the echinocandins. This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37]. In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36]. While there is an association of FKS mutations with resistance, and biochemical data support the resistance mechanism, it has only been conclusively demonstrated that such mutations are sufficient to confer echinocandin resistance in S. cerevisiae [82], [83]. To test whether Fks2 S663P is sufficient to confer echinocandin resistance, we introduced the T1987C mutation into the sensitive laboratory strain BG2 using a strategy involving single-stranded DNA containing the mutation and a silent marker, followed by selection of transformants on medium containing caspofungin. No echinocandin-resistant colonies were obtained following control transformations with single-stranded DNA containing the equivalent wild-type sequence or with a water control, while many resistant colonies were obtained with the sequence containing the T1987C mutation. We assessed resistance of four sequence-verified transformants that harboured both the T1987C and silent mutation via minimum inhibitory concentration (MIC) assays. The transformants displayed resistance similar to clinical isolate G (Figure 2A). Thus, Fks2 S663P is sufficient to confer echinocandin resistance in a susceptible laboratory strain of C. glabrata. Given that specific Fks amino acid substitutions that decrease sensitivity of the 1,3-β-D-glucan synthase enzyme to echinocandins also reduce the enzyme catalytic capacity, the Fks2 S663P mutation may confer a fitness cost in terms of reduced growth or viability in the absence of the drug [36], [39]. To determine if the FKS2 mutations compromises fitness, we monitored growth kinetics of the lab strain BG2 and the progeny harbouring the Fks2 S663P substitution. In clinically relevant conditions, RPMI at 37°C, we found that strains harbouring the Fks2 S663P substitution displayed significantly reduced fitness relative to the parental wild-type laboratory strain BG2 (P<0.01, area under the curve followed by ANOVA, Bonferroni's Multiple Comparison Test, Figure 2B, left panel). Furthermore, we observed a significant reduction in fitness between isolate A and isolate D (P<0.001), which is rescued to some extent in isolate G (P<0.01, Figure 2B, right panel). Thus, the FKS2 mutation that emerged in clinical isolate D is sufficient to confer a high level of caspofungin resistance equivalent to that observed in the late isolate G, however, it is also associated with a cost in terms of reduced fitness in the absence of the drug.
What the sources say
- Supportedcites [36] G Garcia-Effron, 2009, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint., Antimicrob Agents Chemother source
The Results (page not specified) report higher echinocandin IC50 values for mutant glucan synthase than for wild-type enzyme, indicating reduced sensitivity to inhibition. They specifically identify Fks2p substitutions among the mutants with elevated IC50 values. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Results > The FKS2 T1987C (S663P) mutation confers echinocandin resistance and imparts a fitness deficit in a C. glabrata laboratory strain To determine which of the mutations identified by whole genome sequencing contributes to echinocandin resistance we first turned to the most likely candidate resistance gene, FKS2. The FKS2 mutation that emerged in isolate D and was maintained throughout the rest of the series (T1987C) results in substitution of a serine to proline at amino acid 663 in the target of the echinocandins. This FKS2 T1987C (S663P) mutation has been previously associated with high levels of caspofungin resistance in C. glabrata clinical isolates [36], [37]. In vitro biochemical studies established that this mutant Fks2 enzyme displays reduced sensitivity to inhibition by echinocandins, as indicated by a higher kinetic inhibition parameter, as well as decreased catalytic capacity, and reduced enzyme velocity, compared to the wild-type enzyme; notably the binding affinity of the mutant enzyme for echinocandins remains unchanged [36]. While there is an association of FKS mutations with resistance, and biochemical data support the resistance mechanism, it has only been conclusively demonstrated that such mutations are sufficient to confer echinocandin resistance in S. cerevisiae [82], [83]. To test whether Fks2 S663P is sufficient to confer echinocandin resistance, we introduced the T1987C mutation into the sensitive laboratory strain BG2 using a strategy involving single-stranded DNA containing the mutation and a silent marker, followed by selection of transformants on medium containing caspofungin. No echinocandin-resistant colonies were obtained following control transformations with single-stranded DNA containing the equivalent wild-type sequence or with a water control, while many resistant colonies were obtained with the sequence containing the T1987C mutation. We assessed resistance of four sequence-verified transformants that harboured both the T1987C and silent mutation via minimum inhibitory concentration (MIC) assays. The transformants displayed resistance similar to clinical isolate G (Figure 2A). Thus, Fks2 S663P is sufficient to confer echinocandin resistance in a susceptible laboratory strain of C. glabrata. Given that specific Fks amino acid substitutions that decrease sensitivity of the 1,3-β-D-glucan synthase enzyme to echinocandins also reduce the enzyme catalytic capacity, the Fks2 S663P mutation may confer a fitness cost in terms of reduced growth or viability in the absence of the drug [36], [39]. To determine if the FKS2 mutations compromises fitness, we monitored growth kinetics of the lab strain BG2 and the progeny harbouring the Fks2 S663P substitution. In clinically relevant conditions, RPMI at 37°C, we found that strains harbouring the Fks2 S663P substitution displayed significantly reduced fitness relative to the parental wild-type laboratory strain BG2 (P<0.01, area under the curve followed by ANOVA, Bonferroni's Multiple Comparison Test, Figure 2B, left panel). Furthermore, we observed a significant reduction in fitness between isolate A and isolate D (P<0.001), which is rescued to some extent in isolate G (P<0.01, Figure 2B, right panel). Thus, the FKS2 mutation that emerged in clinical isolate D is sufficient to confer a high level of caspofungin resistance equivalent to that observed in the late isolate G, however, it is also associated with a cost in terms of reduced fitness in the absence of the drug.
What the sources say
- Supportedcites [36] G Garcia-Effron, 2009, Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint., Antimicrob Agents Chemother source
Results Table 1 identifies a clinical C. glabrata isolate with the FKS2 T1987C (S663P) mutation and reports a caspofungin MIC of 16 μg/ml, versus 0.06–0.12 μg/ml for wild-type isolates. Materials and Methods identifies the resistant strains as clinical isolates. (LLM, conf=0.94)
- Partly supportedcites [37] CD Pfeiffer, 2010, Breakthrough invasive candidiasis in patients on micafungin., J Clin Microbiol sourceExperimental — accuracy not yet measured
Table 2 (Results; page unavailable) identifies FKS2 S663P in C. glabrata clinical isolates with caspofungin MICs >16 μg/ml, supporting the association with high resistance. Our copy does not identify the underlying nucleotide change as T1987C, so that specific part is unverified. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The echinocandins are the only novel class of antifungal drugs approved for clinical use in decades and target the biosynthesis of the key fungal cell wall component, 1,3-β-D-glucan [3], [20], [32].”
§ Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata > Introduction The emergence of drug resistance is an evolutionary process with a profound impact on human health. The widespread deployment of antimicrobial agents in medicine and agriculture exerts strong selection for organisms with enhanced capacity to survive and reproduce in the presence of drug, which has led to the rapid emergence of drug resistance in diverse pathogen populations [1]–[4]. The evolution of drug resistance compromises the efficacy of drugs that we depend on critically for a myriad of therapeutic interventions, and has striking economic consequences. The annual cost attributable to the evolution of drug resistance in the United States alone exceeds $33 billion to cover treatment of patients with drug-resistant infections, additional pesticides required to manage resistant pests, and loss of crops to resistant pests [5]. The emergence of drug resistance in fungal pathogens is of particular concern given the increasing incidence of invasive fungal infections, and the limited number of antifungal drugs. Fungi can cause life-threatening infectious disease in immunocompromised hosts, as well as in healthy humans, and the incidence of fungal bloodstream infections has increased by 207% in recent decades [6]–[8]. Fungi are eukaryotes and share close evolutionary relationships with their human hosts, which limits the number of drug targets that can be exploited to selectively kill fungal pathogens yet minimize host toxicity [1], [3]. Even with current treatment options, mortality rates due to invasive fungal infections can reach 50–90% depending on the pathogen and patient population [7], [8], demanding new strategies to prevent the evolution of drug resistance and enhance the efficacy of antifungal drugs. The evolution of drug resistance is contingent on genetic variability, the ultimate source of which is mutation. One of the most fundamental questions of central importance to predicting and preventing the evolution of drug resistance is which mutations accompany the evolution of drug resistance in the human host. Developments in sequencing technology [9]–[11] now enable this question to be addressed on a genome-wide scale to reveal the identity of mutations that either confer drug resistance in a clinically relevant context or that modify the fitness consequences of resistance mutations. Whole genome sequencing has been applied to bacteria and has revealed principles underpinning the evolution and transmission of drug-resistant pathogens [12], risk factors for the evolution of drug resistance [13], and population dynamics during the evolution of drug resistance in vitro [14]. In fungi, changes in genome-wide gene expression and chromosomal alterations that accompany the evolution of drug resistance have been monitored in experimental populations that evolved resistance in vitro [15], [16], and targeted sequence and expression analysis of specific genes has been implemented to identify mechanisms of resistance that evolve in the human host [1], [17]. However, a global approach to mapping mutations that underpin the evolution of fungal drug resistance has yet to be achieved. Candida glabrata is a leading fungal pathogens of humans and provides a particularly powerful system for studying the evolution of drug resistance in a human host. Candida species are the fourth most common cause of hospital acquired blood-stream infections and are the most prevalent cause of invasive fungal infection worldwide, with mortality rates approaching 50% [7], [18]. C. glabrata is now second to C. albicans as the most prevalent Candida species isolated from clinical specimens [7], [8], [19]. This is due in part to both intrinsic and rapidly acquired resistance of C. glabrata to the azoles, which are the most widely used class of antifungal drugs and inhibit the biosynthesis of the key sterol in fungal cell membranes, ergosterol [20]. As a consequence, the echinocandins are the front-line therapeutic agent for C. glabrata infections [19]. C. glabrata is closely related to the model yeast Saccharomyces cerevisiae and is placed within the Saccharomyces clade rather than the Candida clade to which the leading cause of candidiasis, C. albicans, belongs [21]–[23]. It is thought that C. glabrata emerged as a human pathogen independently from other Candida species. Notably, gene families associated with pathogenicity in C. albicans including iron acquisition and host cell adhesion and invasion are absent from C. glabrata [24]. C. glabrata is an obligate haploid and mating has never been reported, although two mating types, mating type switching, and other mating and meiotic machinery have been described [25]–[27]. To increase genetic diversity C. glabrata undergoes chromosomal translocations and variation in gene copy number [28], [29], mechanisms that also contribute to C. albicans resistance to azoles [16], [30], [31]. As a haploid, analysis of C. glabrata genome sequence is more facile than in diploids such as C. albicans, where mitotic recombination and gene conversion can inflate the number of polymorphisms that accrue and obscure the signal of those functionally associated with drug resistance or adaptation to the host. Compared to the most widely used antifungal drugs in clinical use for the treatment of systemic infections, the azoles, mechanisms of resistance remain more limited for echinocandins. The echinocandins are the only novel class of antifungal drugs approved for clinical use in decades and target the biosynthesis of the key fungal cell wall component, 1,3-β-D-glucan [3], [20], [32]. The 1,3-β-D-glucan synthases are encoded by FKS1, FKS2, and FKS3 in S. cerevisiae, C. glabrata, and C. albicans, and require a regulatory subunit encoded by RHO1 for activity [3], [20], [32], [33]. It is thought that the echinocandins bind to and inhibit the Fks protein; however, the exact mechanism of inhibition remains unknown [33]. Although the echinocandins have been in clinical use since only 2001, there have been numerous reports of C. glabrata echinocandin resistance in patients [34]–[37]. Thus far, the only echinocandin resistance mechanism described is mutation in the drug target, Fks, particularly in highly conserved hot spots regions [33], [36]–[39]. Such mutations can reduce echinocandin susceptibility of 1,3-β-D-glucan synthase by 2 to 3 log orders relative to the wild-type enzyme [36]. Additional resistance mechanisms may remain to be described given that Fks mutations have not been identified in some echinocandin-resistant isolates [20], [37], [40], and that isolates with identical Fks mutations exhibit different resistance phenotypes with distinct responses to cellular perturbations [41]. Even with azoles, for which resistance mechanisms have been studied for decades, new resistance mechanisms and modulators of resistance continue to be discovered, expanding the repertoire of strategies employed by fungi to survive drug exposure to include mutation in the drug target, overexpression of multidrug-efflux transporters, and metabolic alterations that minimize drug toxicity [3], [20], [32]. In addition to these canonical resistance mechanisms where mutations in relevant genes confer resistance, there is also an emergent paradigm in which regulators of cellular stress responses are crucial for enabling the evolution and maintenance of drug resistance [3], [20], [32]; while mutations in these regulators have not been identified as a cause of resistance, stress response regulators are key resistance modulators critical for enabling the phenotypic effects of resistance acquired by diverse mechanisms. Beyond mapping mutations that confer resistance, there is pressing clinical need to elucidate strategies to block the evolution of drug resistance and abrogate resistance once it has evolved. One of the most well studied examples of a protein that governs the emergence and maintenance of fungal drug resistance is the molecular chaperone Hsp90. Hsp90 regulates the folding and function of diverse client proteins, including many signal transducers [42], [43]. In C. albicans, compromise of Hsp90 function reduces basal tolerance and resistance of clinical isolates to both the azoles and the echinocandins [41], [44], [45]. Hsp90 enables crucial responses to drug-induced stress by orchestrating signaling through the protein phosphatase calcineurin and the protein kinase C (PKC) cell wall integrity signaling cascade [41], [46]. Hsp90 stabilizes the catalytic subunit of calcineurin and the terminal mitogen-activated protein kinase (MAPK) in the Pkc1 cell wall integrity pathway. Genetic or pharmacological compromise of Hsp90 function can enhance the efficacy of antifungals against C. albicans in multiple metazoan models of infection [41], [45]. Notably, Hsp90's role in governing cellular responses to azoles in C. albicans is conserved in S. cerevisiae [44], [47]. In contrast, Hsp90 and calcineurin play a key role in crucial cellular responses to echinocandins in C. albicans, but not in S. cerevisiae [41]. Whether Hsp90 influences drug resistance in C. glabrata remains entirely unknown. In C. glabrata, both calcineurin and PKC signaling have been implicated in basal tolerance to echinocandins [48], [49], though the role of Hsp90 remains unknown as does the impact of any of these regulators on bona fide echinocandin resistance. Here, we provide the first global analysis of mutations accompanying the evolution of fungal drug resistance in a human host. We report on a series of C. glabrata isolates that evolved echinocandin resistance in a patient undergoing treatment with the echinocandin caspofungin for recurring C. glabrata candidemia over a 10-month period. Whole genome sequencing revealed that a mutation occurred in the gene encoding the drug target, FKS2, accompanying a major increase in resistance, as well as 8 other non-synonymous mutations in genes not previously implicated in echinocandin resistance, including CDC6 and CDC55. The FKS2-T1987C(S663P) mutation was sufficient to confer echinocandin resistance in a susceptible laboratory strain; however, the mutant allele also imparted a growth defect in clinically relevant conditions using RPMI medium at 37°C. The fitness cost of resistance was mitigated with further evolution, and this trend was also observed in a murine model of disseminated infection. A CDC6-A511G (K171E) mutation acquired prior to the FKS2-T1987C(S663P) mutation was sufficient to confer a small increase in resistance. Elevated dosage of CDC55, which acquired a C463T(P155S) mutation after FKS2-T1987C(S663P), ameliorated the fitness cost imparted by the FKS2 mutation. To uncover mechanisms that abrogate echinocandin resistance, we turned to Hsp90 and found that genetic or pharmacological compromise of C. glabrata Hsp90 function reduced basal tolerance and resistance of clinical isolates. Compromising calcineurin function pharmacologically or genetically phenocopied compromising Hsp90 function. Caspofungin induced FKS2 expression in a manner that depended upon Hsp90 and calcineurin, providing a molecular mechanism by which Hsp90 and calcineurin regulate echinocandin resistance. Furthermore, one of the clinical isolates in the series is a petite mutant based on morphology and inability to respire; although the petite phenotype was not intrinsically involved in echinocandin resistance, it imparted resistance to the combination of echinocandins and inhibitors of Hsp90 or calcineurin. In a mouse model of candidemia, the petite mutant was rapidly cleared and completely avirulent while infection with the HSP90-repressible strain yielded a reduced fungal burden compared to wild type. Thus, our results provide the first global view of mutations that accompany the evolution of fungal drug resistance in a human host, implicate the first compensatory mutation that mitigates the cost of echinocandin resistance, and suggest a new molecular mechanism regulating echinocandin resistance, with broad therapeutic potential.
What the sources say
- Not checked — no full text of the sourcecites [3] LE Cowen, 2008, The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype., Nat Rev Microbiol source
- Supportedcites [20] RS Shapiro, 2011, Regulatory circuitry governing fungal development, drug resistance, and disease., Microbiol Mol Biol Rev source
The Echinocandins subsection states that echinocandins inhibit (1,3)-β-D-glucan synthase, an enzyme involved in fungal cell wall synthesis. This directly supports the attributed claim about their target. (LLM, conf=0.95)
- Supportedcites [32] LE Cowen, 2008, Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance., Eukaryot Cell source
The ‘ANTIFUNGAL DRUGS AND CLINICAL ANTIFUNGAL RESISTANCE’ section states that echinocandins inhibit (1,3)-β-D-glucan synthase, interfering with biosynthesis of an essential fungal cell-wall polysaccharide. The ‘RESISTANCE TO DRUGS EXERTING CELL WALL STRESS’ section also says they inhibit synthesis of (1,3)-β-D-glucan. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
124 more claims · 11 with their cited sources checked
Create a free account to see all 187 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 39
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to genetic determinants of tolerance level, growth conditions influence the degree of tolerance exhibited by a strain.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas calcineurin inhibitors reduce echinocandin tolerance (measured using MIC assays analyzed after 72 h)68,78.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While its role in drug tolerance, persistence, and stable resistance is documented [19, 20, 21, 22]”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in Candida Glabrata (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, ECN resistance can develop quickly upon the onset of ECN treatment (73, 74).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antifungal drug resistance is most likely accompanied by trade-offs in fungal fitness in certain environments such as the absence of antifungal selection pressure (74, 87, 88).”
From Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris (2022) · cites this paper as [74]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Global analysis of protein localization in budding yeast
Huh, W.-K., Falvo, J. V., Gerke, L. C., Carroll, A. S., Howson, R. W., Weissman, J. S., & O'Shea, E. K. (2003) · Nature · doi:10.1038/nature02026 · Cited by 4,248
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 3×
“infections can reach 50–90% depending on the pathogen and patient population [7,8], demanding new strategies to prevent the evolution of drug resistance and enhance the efficacy of antifungal drugs.”
BackgroundNext-Generation DNA Sequencing Methods
Mardis, E. R. (2008) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164359 · Cited by 2,369 · cited 1×
“Developments in sequencing technology [9–11] now enable this question to be addressed on a genome-wide scale to reveal the identity of mutations that either confer drug resistance in a clinically relevant context or that modify the fitness consequences of resistance mutations.”
BackgroundAntibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294 · cited 1×
“The fitness effects of antibiotic resistance mutations have been studied extensively in bacteria, where most resistance mechanisms are associated with a fitness cost that manifests in reduced growth rate [84].”
BackgroundHSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Dujon, B., Sherman, D., Fischer, G., Durrens, P., Casaregola, S., Lafontaine, I., de Montigny, J., Marck, C., Neuvéglise, C., Talla, E., et al. (2004) · Nature · doi:10.1038/nature02579 · Cited by 1,623 · cited 1×
“cerevisiae with a large number of orthologs between the two species, facilitating bioinformatic analysis [21,22].”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Humans as the World's Greatest Evolutionary Force
Palumbi, S. R. (2001) · Science · doi:10.1126/science.293.5536.1786 · Cited by 1,290 · cited 1×
“pests [5].”
Research works printed but not linked: 1
- 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, Third Edition, Document M27-A3
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Self-citationDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“Inhibition of Hsp90 reduces echinocandin resistance acquired by mutation in the drug target, and resistance that evolved in the human host (Singh et al. 2009; Singh-Babak et al. 2012).”
BackgroundInfluentialSelf-citationAntifungal drug resistance: evolution, mechanisms and impact
Revie, N. M., Iyer, K. R., Robbins, N., & Cowen, L. E. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.02.005 · Cited by 516
Self-citationMolecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
Self-citationEchinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374
The evolution of drug resistance in clinical isolates of Candida albicans.
Ford, C. B., Funt, J. M., Abbey, D., Issi, L., Guiducci, C., Martinez, D. A., Delorey, T., Li, B. Y., White, T. C., Cuomo, C., et al. (2015) · eLife · doi:10.7554/elife.00662 · Cited by 348
“Our study identified substantial genetic diversity in each series, in contrast to the report of only 26 SNPs detected in a single clinical series of Candida glabrata isolates that spanned a 10-month period (Singh-Babak et al., 2012).”
Mechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
The rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
“With the advent of RNA sequencing and whole-genome sequencing, data increasingly suggest that most cells that acquire antifungal resistance undergo multiple other compensatory changes 196 .”
BackgroundEchinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
“glabrata isolates revealed that a subsequent compensatory mutation (CDC55 P155S) mitigated the fitness cost induced by the S663P mutation [32].”
BackgroundAntifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Self-citationThe Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
Zhang, J., Li, L., Lv, Q., Yan, L., Wang, Y., & Jiang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00691 · Cited by 245
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“glabrata to echinocandins was also analyzed by whole genome sequencing of serially isolated strains obtained from a patient subjected to caspofungin treatment [145].”
BackgroundFungal Cell Wall: Emerging Antifungals and Drug Resistance.
Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02573 · Cited by 223
Combinatorial strategies for combating invasive fungal infections
Spitzer, M., Robbins, N., & Wright, G. D. (2017) · Virulence · doi:10.1080/21505594.2016.1196300 · Cited by 218
Schwarzmüller, T., Ma, B., Hiller, E., Istel, F., Tscherner, M., Brunke, S., Ames, L., Firon, A., Green, B., Cabral, V., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004211 · Cited by 191
“wall homeostasis in fungal pathogens [36,83,84].”
BackgroundResultFungal resistance to echinocandins and the MDR phenomenon in Candida glabrata
Healey, K., & Perlin, D. S. (2018) · doi:10.20944/preprints201808.0306.v1 · Cited by 194
Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Healey, K. R., & Perlin, D. S. (2018) · Journal of Fungi · doi:10.3390/jof4030105 · Cited by 194
“, WSC1, MKK1, BCK1, SLT2) [43–45], Hsp90 and calcineurin signaling [46,47], and chromatin remodeling [48,49], have been shown to abrogate echinocandin tolerance or adaptation when disrupted or targeted in C.”
BackgroundJuvvadi, P. R., Lee, S. C., Heitman, J., & Steinbach, W. J. (2017) · Virulence · doi:10.1080/21505594.2016.1201250 · Cited by 172
Self-citationUpdate on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174
Drug-Resistant Candida glabrata Infection in Cancer Patients
Farmakiotis, D., Tarrand, J. J., & Kontoyiannis, D. P. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2011.140685 · Cited by 152
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Kim, S. H., Iyer, K. R., Pardeshi, L., Muñoz, J. F., Robbins, N., Cuomo, C. A., Wong, K. H., & Cowen, L. E. (2019) · mBio · doi:10.1128/mbio.02529-18 · Cited by 136
Self-citationGarcía‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 143
Candida glabrata: A Lot More Than Meets the Eye
Kumar, K., Askari, F., Sahu, M. S., & Kaur, R. (2019) · Microorganisms · doi:10.3390/microorganisms7020039 · Cited by 128
“Both these signaling cascades are also required to survive the azole and echinocandin antifungal stress [54,91,99,100].”
BackgroundPathogenesis of Dermatophytosis: Sensing the Host Tissue
Martinez-Rossi, N. M., Peres, N. T. A., & Rossi, A. (2016) · Mycopathologia · doi:10.1007/s11046-016-0057-9 · Cited by 148
Sekyere, J. O., & Asante, J. (2018) · Future Microbiology · doi:10.2217/fmb-2017-0172 · Cited by 141
Molecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“Echinocandin-resistant Candida isolates have impaired fitness as compared with isogenic FKS wild-type strains [43,44].”
BackgroundEchinocandins: production and applications
Emri, T., Majoros, L., Tóth, V., & Pócsi, I. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-4761-9 · Cited by 123
“…of data suggests that echinocandin exposure as a stress signal activates cell wall remodeling via protein kinase C (PKC), HOG, Ca 2+ -calcineurin and HSP90 pathways (Fortwendel et al. 2010; Singh et al. 2009; Singh-Babak et al. 2012; Stevens et al. 2006; Walker et al. 2008, 2012; Wiederhold 2007).”
BackgroundKsiezopolska, E., Schikora-Tamarit, M. À., Beyer, R., Nunez-Rodriguez, J. C., Schüller, C., & Gabaldón, T. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.084 · Cited by 107
“glabrata, a large degree of genomic and phenotypic variation has been described between and within genetically diverse clades(19,20) and even within clonal populations infecting a patient.(21,22) Previous studies on in vitro-acquired drug resistance in C.”
Elucidating Drug Resistance in Human Fungal Pathogens
Xie, J. L., Polvi, E. J., Shekhar-Guturja, T., & Cowen, L. E. (2014) · Future Microbiology · doi:10.2217/fmb.14.18 · Cited by 100
Self-citationEchinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99
“Hsp90 induces tolerance to echinocandin drugs through its principal client protein calcineurin and the downstream effector crz1 [94, 95].”
Antifungal Drug Discovery: The Process and Outcomes
Calderone, R., Sun, N., Gay-Andrieu, F., Groutas, W., Weerawarna, P., Prasad, S., Alex, D., & Li, D. (2014) · Future Microbiology · doi:10.2217/fmb.14.32 · Cited by 97
Resistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
The fungal Achilles’ heel: targeting Hsp90 to cripple fungal pathogens
Cowen, L. E. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.03.005 · Cited by 104
Self-citationKim, S. H., Clark, S. T., Surendra, A., Copeland, J. K., Wang, P. W., Ammar, R., Collins, C., Tullis, D. E., Nislow, C., Hwang, D. M., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005308 · Cited by 92
“This stands in contrast to the rapid emergence of drug resistance in fungal populations in the host that has been observed with Candida species from patients with AIDS or Crohn’s disease [15,16], and with the high frequency of azole-resistant A.”
ResultSelf-citationDrug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Wang, E., Farmakiotis, D., Yang, D., McCue, D. A., Kantarjian, H. M., Kontoyiannis, D. P., & Mathisen, M. S. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv087 · Cited by 82
Yang, F., Zhang, L., Wakabayashi, H., Myers, J., Jiang, Y., Cao, Y., Jimenez-Ortigosa, C., Perlin, D. S., & Rustchenko, E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00071-17 · Cited by 81
“As shown with the clinical isolates, evolution of clinical resistance to caspofungin can involve mutations in genes that are different from FKS genes and that confer a small increase in resistance or promote increased fitness (36).”
BackgroundFitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., O’Meara, T. R., & Cowen, L. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.009 · Cited by 80
Self-citationAntifungal drug resistance in Candida species
Morace, G., Perdoni, F., & Borghi, E. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.09.002 · Cited by 80
“These strains, displaying a reduced susceptibility to echinocandins, showed mutations in the FKS genes (FKS1, FKS2 and FKS3) that correlated with amino acid substitutions in the 1,3-b-Dglucan synthase, the target of the echinocandins [5,7–10,12, 31–44].”
BackgroundRogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Farmakiotis, D., & Kontoyiannis, D. P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.019 · Cited by 83
Tipping the balance both ways: drug resistance and virulence in Candida glabrata
Vale-Silva, L. A., & Sanglard, D. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov025 · Cited by 67
“The study could however not detect chromosomal changes due 1 to the used sequencing technology (Singh-Babak et al., 2012).”
BackgroundMethodInfluentialJacob, T. R., Peres, N. T. A., Martins, M. P., Lang, E. A. S., Sanches, P. R., Rossi, A., & Martinez-Rossi, N. M. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01241 · Cited by 68
Matta, R., Pochampally, J., Dhoddi, B. N., et al. (2023) · BMC Chemistry · doi:10.1186/s13065-023-00965-8 · Cited by 63
“The Minimum Inhibitory Concentration (MIC) [38] of the compounds against a bacterial activity was determined using the broth dilution method and is represented in the below Table 1.”
MethodInfluentialComparative Genomics of Two Sequential Candida glabrata Clinical Isolates
Vale-Silva, L., Beaudoing, E., Tran, V. D. T., & Sanglard, D. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.117.042887 · Cited by 61
“These data indicate extensive divergence between the two genomes, however they are in general agreement with the analysis deduced from other C. glabrata genomes (Singh-Babak et al. 2012).”
ResultAntifungal activity of newly synthesized chemodegradable dicephalic-type cationic surfactants
Paluch, E., Piecuch, A., Obłąk, E., Lamch, Ł., & Wilk, K. A. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.01.020 · Cited by 61
Losada, L., Sugui, J. A., Eckhaus, M. A., Chang, Y. C., Mounaud, S., Figat, A., Joardar, V., Pakala, S. B., Pakala, S., Venepally, P., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004834 · Cited by 58
“Whole-genome sequencing of resistant strains was recently used to identify novel drug-resistance mechanisms in Escherichia coli [15], Candida glabrata [16], and Plasmodium falciparum [17], among others.”
BackgroundIn Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates
Lee, Y., Lee, K.-T., Lee, S. J., Beom, J. Y., Hwangbo, A., Jung, J. A., Song, M. C., Yoo, Y. J., Kang, S. H., Averette, A. F., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-18 · Cited by 58
“MICs and fractional inhibitory concentrations (FIC) were calculated as described previously (63, 64).”
MethodSelf-citationCarreté, L., Ksiezopolska, E., Gómez-Molero, E., Angoulvant, A., Bader, O., Fairhead, C., & Gabaldón, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00112 · Cited by 58
“Several recent studies have compared genome sequences from C. glabrata isolates obtained from the same patient (Singh-Babak et al., 2012; Biswas et al., 2017; Håvelsrud and Gaustad, 2017; Vale-Silva et al., 2017; Barber et al., 2018; Carreté et al., 2018).”
BackgroundGale, A. N., Sakhawala, R. M., Levitan, A., Sharan, R., Berman, J., Timp, W., & Cunningham, K. W. (2020) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.120.401595 · Cited by 56
Garnaud, C., Botterel, F., Sertour, N., Bougnoux, M.-E., Dannaoui, E., Larrat, S., Hennequin, C., Guinea, J., Cornet, M., & Maubon, D. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv139 · Cited by 55
Wu, Z., Liu, Y., Feng, X., Liu, Y., Wang, S., Zhu, X., Chen, Q., & Pan, S. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2013.11.011 · Cited by 53
“Despite many methods being available for the identification of Candida spp, the currently available methods are not able to discriminate subspecies, and molecular typing methods such as whole genome sequencing, a highly discriminatory typing method, are required to identify sources of transmission or outbreaks.(16) Cu…”
MethodPolvi, E. J., Averette, A. F., Lee, S. C., Kim, T., Bahn, Y.-S., Veri, A. O., Robbins, N., Heitman, J., & Cowen, L. E. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006350 · Cited by 52
Self-citationPais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C. (2019) · Microbial Cell · doi:10.15698/mic2019.03.670 · Cited by 51
“glabrata isolates recovered over a 10-month period from a patient that underwent caspofungin treatment for bloodstream candidemia [103].”
BackgroundBiswas, C., Marcelino, V. R., Van Hal, S., Halliday, C., Martinez, E., Wang, Q., Kidd, S., Kennedy, K., Marriott, D., Morrissey, C. O., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02946 · Cited by 49
Discovery of a Novel Antifungal Agent in the Pathogen Box
Mayer, F. L., & Kronstad, J. W. (2017) · mSphere · doi:10.1128/msphere.00120-17 · Cited by 49
“Assays for the MIC of MMV688271 were performed in sterile 96-well microtiter plates (Greiner) by using a previously published broth microdilution approach (34, 35).”
MethodO'Meara, T. R., & Cowen, L. E. (2014) · Cellular Microbiology · doi:10.1111/cmi.12266 · Cited by 48
“…such as the protein phosphatase calcineurin or elements of the protein kinase C (PKC) pathway, Hsp90 enables the phenotypic effects of resistance mutations, and thus the development of drug resistance (Cowen and Lindquist, 2005; Cowen et al., 2006; Singh et al., 2009; Singh-Babak et al., 2012).”
BackgroundSelf-citationJensen, R. H., Johansen, H. K., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-12 · Cited by 47
Minimum Inhibitory Concentration (MIC) Assay for Antifungal Drugs
Xie, J., Singh-Babak, S., & Cowen, L. (2012) · BIO-PROTOCOL · doi:10.21769/bioprotoc.252 · Cited by 46
Self-citationCan We Improve Antifungal Susceptibility Testing?
Durand, C., Maubon, D., Cornet, M., Wang, Y., Aldebert, D., & Garnaud, C. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.720609 · Cited by 52
Progress and prospects for targeting Hsp90 to treat fungal infections
VERI, A., & COWEN, L. E. (2014) · Parasitology · doi:10.1017/s0031182013002072 · Cited by 43
“Calcineurin is also required for virulence in species of Candida, Cryptococcus and Aspergillus (Bader et al. 2003; Sanglard et al. 2003; Steinbach et al. 2006; Miyazaki et al. 2010b; Reedy et al. 2010; Chen et al. 2011, 2012, 2013; Singh-Babak et al. 2012; Zhang et al. 2012; Juvvadi et al. 2013).”
BackgroundSelf-citationEchinocandin Resistance in Candida Species: a Review of Recent Developments
Wiederhold, N. P. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0549-2 · Cited by 48
Fungicidal Potency and Mechanisms of θ-Defensins against Multidrug-Resistant Candida Species
Basso, V., Garcia, A., Tran, D. Q., Schaal, J. B., Tran, P. A., Ngole, D., Aqeel, Y., Tongaonkar, P., Ouellette, A. J., & Selsted, M. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-18 · Cited by 44
“Cells were suspended in test medium (RPMI 1640 medium, 25 mM MOPS, 2 mM L-glutamine) to 104 CFU per ml (73).”
MethodSanglard, D. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007478 · Cited by 42
Traven, A., Jänicke, A., Harrison, P., Swaminathan, A., Seemann, T., & Beilharz, T. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046243 · Cited by 37
“glabrata [41,42,43,44,45]; reviewed in [46]).”
Repurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity
Sun, N., Li, D., Zhang, Y., Killeen, K., Groutas, W., & Calderone, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-17147-x · Cited by 36
An insight into new strategies to combat antifungal drug resistance
Zheng, Y., Ma, Y., Ding, Y., Chen, X., & Gao, G. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s185833 · Cited by 38
“15 The combined use of Hsp90 inhibitors and echinocandins has fungicidal effect against azole-resistant strains of A. fumigatus .”
Fitness Studies of Azole-Resistant Strains of Aspergillus fumigatus
Valsecchi, I., Mellado, E., Beau, R., Raj, S., & Latgé, J.-P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01594-15 · Cited by 35
“deed been demonstrated for only very few yeast strains (22, 23).”
BackgroundJenull, S., Shivarathri, R., Tsymala, I., Penninger, P., Trinh, P.-C., Nogueira, F., Chauhan, M., Singh, A., Petryshyn, A., Stoiber, A., et al. (2022) · mBio · doi:10.1128/mbio.00799-22 · Cited by 32
“Moreover, ECN resistance can develop quickly upon the onset of ECN treatment (73, 74).”
BackgroundAnderson, M. Z., Gerstein, A. C., Wigen, L., Baller, J. A., & Berman, J. G. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004436 · Cited by 39
“Furthermore, while aneuploidy in general often incurs a high fitness cost, some aneuploidies have very little cost, even under non-selective conditions [22–24].”
BackgroundLiang, J., Cheng, T., Huang, Y., et al. (2018) · AMB Express · doi:10.1186/s13568-018-0620-5 · Cited by 33
Barber, A. E., Weber, M., Kaerger, K., Linde, J., Gölz, H., Duerschmied, D., Markert, A., Guthke, R., Walther, G., & Kurzai, O. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01628-18 · Cited by 32
Fu, C., Beattie, S. R., Jezewski, A. J., Robbins, N., Whitesell, L., Krysan, D. J., & Cowen, L. E. (2022) · Genetics · doi:10.1093/genetics/iyab164 · Cited by 31
Self-citationUsing genomics to understand the mechanisms of virulence and drug resistance in fungal pathogens
Schikora-Tamarit, M. À., & Gabaldón, T. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211123 · Cited by 35
Sah, S. K., Hayes, J. J., & Rustchenko, E. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009564 · Cited by 26
“These “alternative” mechanisms have been brought to light by dozens of clinical isolates of Candida species that display a wide range of increased MIC values for ECNs, including some at or below the MIC breakpoints, but, importantly, without canonical FKS1 mutations [7–10].”
BackgroundInfluentialArastehfar, A., Daneshnia, F., Hovhannisyan, H., Fuentes, D., Cabrera, N., Quinteros, C., Ilkit, M., Ünal, N., Hilmioğlu-Polat, S., Jabeen, K., et al. (2023) · mBio · doi:10.1128/mbio.01180-23 · Cited by 27
“Strikingly, petites are more abundant in urine samples (7, 12, 17), and a recent study identified 10.2% (15/146) petite isolates in a collection of C. glabrata clinical isolates from diverse clinical samples (7).”
BackgroundResultInfluentialRobbins, N., & Cowen, L. E. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.071 · Cited by 24
Self-citationLi, Y., Lan, N., Xu, L., & Yue, Q. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9382-x · Cited by 23
Basso, V., Tran, D. Q., Schaal, J. B., Tran, P. A., Eriguchi, Y., Ngole, D., Cabebe, A. E., Park, A. Y., Beringer, P. M., Ouellette, A. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53402-z · Cited by 25
Biosynthesis of Nonimmunosuppressive FK506 Analogues with Antifungal Activity
Beom, J. Y., Jung, J. A., Lee, K.-T., Hwangbo, A., Song, M., Lee, Y., Lee, S. J., Oh, J. H., Ha, S., Nam, S., et al. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00144 · Cited by 25
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch44 · Cited by 27
Self-citationRosenwald, A. G., Arora, G., Ferrandino, R., Gerace, E. L., Mohammednetej, M., Nosair, W., Rattila, S., Subic, A. Z., & Rolfes, R. (2016) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.116.032490 · Cited by 23
“Noneofthese genesarecurrentlyassociatedwithclinicalresistance;ratherresistancein theclinicisassociatedprimarilywithmutationsin FKS1 and FKS2 (Arendrup et al. 2012; Duran-Valle et al. 2012; Singh-Babak et al. 2012; Alexander et al. 2013; Borghi et al. 2014; Pham et al. 2014).”
Fungal cell barriers and organelles are disrupted by polyhexamethylene biguanide (PHMB)
Ntow‐Boahene, W., Papandronicou, I., Miculob, J., & Good, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-29756-w · Cited by 28
Evaluation of the Potential Probiotic Yeast Characteristics with Anti-MRSA Abilities
Shen, Y., Bai, X., Zhang, Y., Gao, Q., Bu, X., Xu, Y., & Guo, N. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09942-4 · Cited by 23
Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Biswas, C., Chen, S. C. ‐., Halliday, C. L., Martinez, E. M., Rockett, R. J., Wang, Q., Timms, V. J., Dhakal, R., Sadsad, R., Kennedy, K., et al. (2017) · Journal of Visualized Experiments · doi:10.3791/56714 · Cited by 23
Yue, Q., Li, Y., Chen, L., Zhang, X., Liu, X., An, Z., & Bills, G. F. (2018) · Environmental Microbiology · doi:10.1111/1462-2920.14089 · Cited by 22
“A plethora of fungal genome data has also stimulated research on drug resistance of fungal pathogens against echinocandins (Singh-Babak et al., 2012).”
BackgroundBordallo-Cardona, M. Á., Marcos-Zambrano, L. J., Sánchez‐Carrillo, C., de la Pedrosa, E. G. G., Cantón, R., Bouza, E., Escribano, P., & Guinea, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01982-17 · Cited by 26
Wride, D. A., Pourmand, N., Bray, W. M., Kosarchuk, J. J., Nisam, S. C., Quan, T. K., Berkeley, R. F., Katzman, S. J., Hartzog, G. A., Dobkin, C., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb00146j · Cited by 21
“For example, the target of a new anti-tuberculosis drug was identified by whole-genome sequencing of resistant clones[22], and NGS approaches have been used to identify mutations responsible for echinocandin resistance in Candida galbrata[23].”
Antifungal resistance, combinations and pipeline: oh my!
Stover, K. R., Hawkins, B. K., Keck, J. M., Barber, K. E., & Cretella, D. A. (2023) · Drugs in Context · doi:10.7573/dic.2023-7-1 · Cited by 22
“53 55 Modifications in mRNA stability have also been implicated in azole resistance.”
BackgroundWells, M. L., Washington, O. L., Hicks, S. N., Nobile, C. J., Hartooni, N., Wilson, G. M., Zucconi, B. E., Huang, W., Li, L., Fargo, D. C., et al. (2015) · Molecular Microbiology · doi:10.1111/mmi.12913 · Cited by 20
“Growth curves were performed by inoculating cells from an overnight culture grown in YPD at 30°C to a starting OD600 = 0.01 in 100 μl YPD medium as described in Singh-Babak et al. (2012).”
MethodInfluentialEvaluation of Polymorphic Locus Sequence Typing for Candida glabrata Epidemiology
Katiyar, S. K., Shiffrin, E., Shelton, C. A., Healey, K. R., Vermitsky, J., & Edlind, T. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.03106-15 · Cited by 22
“enzyme digestion (14, 23, 31), (iii) multilocus variable-number”
BackgroundResultDurán-Aranguren, D. D., Yamakawa, C. K., Ordeñana, J., Sierra, R., Posada, J. A., & Mussatto, S. I. (2024) · Biomass and Bioenergy · doi:10.1016/j.biombioe.2024.107514 · Cited by 22
Misas, E., Seagle, E. E., Jenkins, E. N., Rajeev, M., Hurst, S. F., Nunnally, N. S., Bentz, M. L., Lyman, M., Berkow, E. L., Harrison, L. H., et al. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-23 · Cited by 26
“In addition, several studies compared the related ness among C. glabrata isolates from the same patient using other molecular techniques (29, 30, 44, 45), and in general, they found similarity among isolates.”
Ceballos-Garzon, A., Monteoliva, L., Gil, C., Alvarez-Moreno, C., Vega-Vela, N. E., Engelthaler, D. M., Bowers, J., Le Pape, P., & Parra-Giraldo, C. M. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab454 · Cited by 18
Imbert, S., Castain, L., Pons, A., Jacob, S., Meyer, I., Palous, M., Vézinet, C., Langeron, O., Hennequin, C., Monsel, A., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.07.025 · Cited by 19
Inferring fungal growth rates from optical density data
Hameed, T., Motsi, N., Bignell, E., & Tanaka, R. J. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012105 · Cited by 20
Metadata
- Authors
- Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E.
- Affiliations
- University of Toronto (CA)
- Stanford University (US)
- Duke Medical Center (US)
- Mount Sinai Hospital (CA)
- University of Alberta (CA)
- Corresponding author
- Cowen, Leah E.
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-17
- Volume
- 8
- Issue
- 5
- Pages
- e1002718
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC3355103
- OpenAlex
- W2019892034
- Cited by
- 205
- References
- 133
- Citations by year
- 2026: 15 · 2025: 15 · 2024: 10 · 2023: 11 · 2022: 11 · 2021: 15 · 2020: 15 · 2019: 14 · 2018: 22 · 2017: 16 · 2016: 14 · 2015: 18 · 2014: 22 · 2013: 4 · 2012: 3
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure (University of Bath) (publishedVersion, cc-by)
- Bristol Research (University of Bristol) (publishedVersion)
- The University of Bath Online Publications Store (The University of Bath) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Funders
- Burroughs Wellcome Fund
- University of Toronto
- National Institutes of Health
- Center for AIDS Research, Duke University (AI 064518)
- Center for AIDS Research, University of Washington
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada (355965-2009)
- National Institute of Allergy and Infectious Diseases (R01AI050438, P30AI064518)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- echinocandin resistance, Candida glabrata, caspofungin, FKS2, CDC6, Cdc55, HSP90, calcineurin, fitness cost, compensatory mutations, drug resistance evolution, petite mutants, mitochondrial respiration, Hsp90 inhibitors, calcineurin inhibitors, antifungal resistance
- MeSH terms
- Caspofungin, Antifungal Agents, Base Sequence, Female, Fungal Proteins, Glucosyltransferases, Humans, Microbial Sensitivity Tests, Middle Aged, Polymorphism, Genetic, Genome, Fungal, Sequence Analysis, DNA, HSP90 Heat-Shock Proteins, Evolution, Molecular, Calcineurin, Drug Resistance, Fungal, Candida glabrata, Echinocandins, Lipopeptides, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.